A Study of Bleximenib or Placebo in Combination With Venetoclax and Azacitidine in People With Acute Myeloid Leukemia

Full Title

A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.

Protocol
26-325
Phase
Phase III (phase 3)
Investigator
Eytan M. Stein
Co-Investigators
Kuo-Kai Chin
Diseases
Leukemia › Acute Myelocytic Leukemia
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06852222
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description